KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial. PMID 40858558 · Nat Commun · 2025-Aug-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: Protocol for a Pilot Randomized Controlled Trial. PMID 40857715 · JMIR Res Protoc · 2025-Aug-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety of alisertib in the treatment of solid and hematological cancers: A systematic review and meta-analysis of randomized controlled trials. PMID 40856692 · J Oncol Pharm Pract · 2025-Aug-26 This is a systematic review and meta-analysis focused on safety outcomes (adverse events). It is not an original report of a single randomized trial, and it does not report a time-to-event efficacy endpoint (OS, PFS, etc.) as the primary or key secondary outcome.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept. PMID 40554429 · Blood Adv · 2025-Aug-26 The trial is a randomized controlled trial in oncology (hematologic malignancies) with drug intervention and time-to-event endpoints. However, the phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata, which is a required criterion for eligibility. Therefore, it cannot be confirmed as meeting all inclusion criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. PMID 40334072 · Blood Adv · 2025-Aug-26 The study meets the criteria for being an original, randomized, phase III oncology trial with a drug intervention. However, the primary reported efficacy endpoint (MMR) is a categorical response rate, not the required primary or key secondary time-to-event endpoint (e.g., OS, PFS). No time-to-event signal is present in the provided metadata.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS. PMID 40334070 · Blood Adv · 2025-Aug-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Beyond Analgesia: Psychobiotics as an Adjunctive Approach to Pain Management in Gastrointestinal Oncology-A Post Hoc Analysis from the ProDeCa Study. PMID 40944142 · Nutrients · 2025-Aug-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mini-laparotomy versus transrectal natural orifice specimen extraction for minimally invasive colorectal cancer surgery: study protocol for a randomized controlled trial (MINITR-NOSE trial, TCAR2514 protocol). PMID 40855494 · Trials · 2025-Aug-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment. PMID 40855285 · BMC Cancer · 2025-Aug-25 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Smartphone App-Guided Pulmonary Rehabilitation in Chronic Respiratory Diseases: Randomized Controlled Trial. PMID 40854157 · JMIR Mhealth Uhealth · 2025-Aug-25 The study is a randomized controlled trial of a smartphone app for pulmonary rehabilitation in chronic respiratory diseases, including some patients with lung cancer. However, it does not meet the eligibility criteria because it is not primarily an oncology trial, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint (OS, PFS, etc.) as its primary or key secondary outcome. The primary endpoint is 6-minute walk test distance.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Long-term oncological safety of robotic total gastrectomy for locally advanced proximal gastric cancer: a 5-year noninferiority comparison based on the FUGES-014 study]. PMID 40850834 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Aug-25 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Systematic referral to palliative care in patients attending dedicated emergency units from French comprehensive anticancer centres: the prospective multicentre randomised comparative clinical trial PALLU. PMID 40850913 · BMJ Open · 2025-Aug-24 This record is a protocol for a randomized trial without results. While it meets criteria for oncology, human subjects, randomization, and a time-to-event endpoint (overall survival as a secondary objective), it is ineligible because: 1) It is a protocol, not an original result report; 2) The intervention is a palliative care referral strategy, not a drug-containing intervention (no drug is named or described as part of the experimental arm); 3) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis Based on 14 Randomized Clinical Trials. PMID 40940844 · Cancers (Basel) · 2025-Aug-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impacts of omega-3 fatty acids intervention on immune functions and clinical outcomes in surgical gastric cancer patients: a systematic review and trial sequential meta-analysis. PMID 40849447 · BMC Cancer · 2025-Aug-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. PMID 40848059 · Cancer Chemother Pharmacol · 2025-Aug-23 The study is an exposure-response analysis of efficacy (MM response) and safety for asciminib in CML, referencing Phase III trials but not reporting a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR data. The primary/key secondary endpoints are MM response rates and safety incidences, which do not meet the time-to-event requirement for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of utilizing a hypertonic saline solution and mannitol to improve brain relaxation during craniotomy in patients with brain tumours: a prospective randomized controlled trial. PMID 40846709 · Sci Rep · 2025-Aug-22 The study is an oncology-related randomized trial comparing two drug interventions, but its primary efficacy endpoint is not a time-to-event outcome. Therefore, it does not meet the core requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. PMID 40454634 · N Engl J Med · 2025-Aug-21 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. PMID 40561369 · J Clin Oncol · 2025-Aug-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiotherapy quality assurance program of ongoing clinical trial using stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC): a dummy run study of a prospective, randomized, multicenter phase III trial (KGOG 3064/KROG 2204). PMID 40826041 · BMC Cancer · 2025-Aug-18 The record describes a quality assurance sub-study for an ongoing Phase III trial, not the primary efficacy results. No time-to-event outcomes are reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer. PMID 40819868 · BMJ Open · 2025-Aug-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Multiparametric MRI for local staging in patients with suspected muscle-invasive bladder cancer: study protocol for a multicentre, non-inferiority randomised controlled trial (the BladParadigm study). PMID 40819867 · BMJ Open · 2025-Aug-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial. PMID 40819029 · BMC Cancer · 2025-Aug-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Diet and physical activity in colorectal cancer patients: A research protocol of a randomized controlled study. PMID 40837756 · World J Gastrointest Oncol · 2025-Aug-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ACT 2 Clinical Trial Design: Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living with HIV. PMID 40832398 · medRxiv · 2025-Aug-14 The record describes a Phase 2b feasibility trial protocol for cervical precancer treatment in HIV-positive women. It is a randomized trial with a drug intervention (5-fluorouracil), but it is not a Phase III/IIIb or Phase II/III trial, it is not an original result report (it is a design/protocol paper), and the primary/secondary outcomes are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS) but rather acceptability, feasibility, and histological/HPV clearance at fixed time points. Therefore, it does not meet the required criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of Qingbu Weijing decoction in treatment stable bronchiectasis: study protocol for a multicenter, double- blind, randomized and placebo-controlled trial. PMID 40813996 · BMC Complement Med Ther · 2025-Aug-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety meta-analysis. PMID 40804462 · Cancer Metastasis Rev · 2025-Aug-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial. PMID 40499144 · Clin Cancer Res · 2025-Aug-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Textbook outcome in low rectal cancer patients undergoing laparoscopic or open surgery: 3-year results from the multicentric LASRE Trial. PMID 40804342 · Int J Colorectal Dis · 2025-Aug-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Interventions for anal canal intraepithelial neoplasia. PMID 40801169 · Cochrane Database Syst Rev · 2025-Aug-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201. PMID 40609265 · Vaccine · 2025-Aug-13 The study is a Phase III randomized trial of a drug intervention (vaccine) in oncology (preventing cancer precursor), but it is a protocol publication without results. Furthermore, the primary endpoint (incidence of persistent oral HPV infection) is an infection incidence endpoint, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of exercise interventions on cardiotoxicity in patients with breast cancer undergoing chemotherapy: a study protocol for a quasi-randomised controlled trial. PMID 40803741 · BMJ Open · 2025-Aug-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. PMID 40792645 · Ann Surg · 2025-Aug-12 The study is an oncology RCT with drug interventions, but its primary endpoint is the incidence of major surgical complications, which is a binary safety/morbidity outcome, not a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Telemedicine follow-up for pre-malignant and malignant glottic lesions: a randomised controlled trial study protocol comparing care close to home versus standard of care. PMID 40791158 · Acta Oncol · 2025-Aug-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial. PMID 40249856 · Blood Adv · 2025-Aug-12 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy. PMID 40790765 · Breast Cancer Res · 2025-Aug-11 The study meets all other criteria but the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided record. Eligibility requires explicit confirmation of a definitive trial phase.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies. PMID 40787733 · Cochrane Database Syst Rev · 2025-Aug-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). PMID 40554738 · J Clin Oncol · 2025-Aug-10 The study is a randomized oncology trial with time-to-event endpoints, but it compares two surgical/procedural interventions (surgery vs. radiofrequency ablation) and does not involve a drug-containing intervention, which is a required criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial. PMID 40540704 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. PMID 40532125 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer. PMID 40493877 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer. PMID 40424564 · J Clin Oncol · 2025-Aug-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial. PMID 40233286 · J Clin Oncol · 2025-Aug-10 The record is excluded because it does not meet two key criteria for inclusion: 1) it is a non-drug intervention study (radiotherapy dose comparison, not a drug-containing arm), and 2) it does not have a primary or key secondary time-to-event efficacy endpoint (the primary endpoint is a quality-of-life score, and the secondary is a cumulative incidence, not a time-to-event analysis).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21). PMID 40783751 · BMC Cancer · 2025-Aug-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Evaluating the effects of a resistance exercise intervention for sarcopenia in patients receiving neoadjuvant chemotherapy for breast cancer: study protocol for a randomized controlled trial. PMID 40783722 · BMC Cancer · 2025-Aug-09 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparing the effectiveness of implementation strategies to improve liver and colon cancer screening for Veterans: protocol for a large cluster-randomized implementation study. PMID 40783525 · Implement Sci · 2025-Aug-09 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Can preoperative CT angiography and three-dimensional reconstruction of the mesenteric artery of the colon improve laparoscopic colectomy and postoperative rehabilitation in patients with colon cancer? A pilot randomized control study. PMID 40779208 · Int J Colorectal Dis · 2025-Aug-08 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
[Interpretation and implications of the phase Ⅲ KEYNOTE-689 trial in head and neck squamous cell carcinoma]. PMID 40890052 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2025-Aug-07 The record appears to be a commentary or interpretation article about a Phase III trial, not the original trial report with primary or secondary efficacy results. Without an abstract or clear evidence of reporting trial outcomes, it cannot be considered an eligible primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of nurse-led intervention programs based on spiritual care on the resilience and death anxiety in parents of children and adolescents with cancer, a randomized clinical trial. PMID 40775798 · BMC Psychol · 2025-Aug-07 Study is a randomized trial in an oncology context but evaluates a non-drug nursing intervention (spiritual care) with psychological endpoints, lacking any drug intervention or time-to-event efficacy endpoint as defined.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Implications of the API-CAT Trial for Extended Secondary Prophylaxis of Cancer-associated Venous Thromboembolism: Guidance from an Expert Panel. PMID 40774336 · Hamostaseologie · 2025-Aug-07 The record is an expert consensus/guidance paper on the API-CAT trial, not the original trial report. It discusses VTE recurrence as the efficacy endpoint, which is a safety/prophylaxis endpoint, not a standard oncology efficacy endpoint (OS, PFS, DFS). The report type is secondary (expert consensus).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Design of a randomized tobacco cessation trial among FDNY World Trade Center responders in a lung cancer screening program. PMID 40765018 · Addict Sci Clin Pract · 2025-Aug-05 This is a trial protocol for a randomized smoking cessation study integrated into a lung cancer screening program. While it is randomized, involves humans, is oncology-related, and includes a drug (varenicline), it is not a report of results from a Phase III/IIIb or Phase II/III oncology randomized trial with a time-to-event efficacy endpoint. It lacks results and the primary outcomes are not time-to-event.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -